aRCC: 1L Treatment Options and Patient Management


ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA-4 Bispecific Checkpoint Inhibitor, as Monotherapy With Advanced RCC: Preliminary Results From the FTIH Trial

139 views
June 30, 2022
Comments 0
Login to view comments. Click here to Login